Kymera Investor Day Presentation Deck
KT-474 Achieved Near Complete and Sustained IRAK4 Degradation
with Multiple Daily Oral Doses (14 Days)
Absolute IRAK4 Levels
Mean % Reduction of IRAK4
Absolute IRAK4 Levels
Mean (SE)[fmol/µg protein]
●
1.5
●
1.0
0.5
0.0
1 2 3 4
7
14
Day
17
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
21
Placebo
25 mg QD
50 mg QD
100 mg QD
200 mg QD*
28
Mean (± SE) Percent IRAK4
Change from Baseline
50
-20
-40
-60
-80
• Detected by mass spectrometry in circulating PBMC
Steady state IRAK4 reduction achieved between Days 7 and 14
Recovery towards baseline by Day 28 (2 weeks after last dose)
MAD 2 through 4 approached Lower Limit of Quantitation (LLOQ)
-100
1 2 3 4
* Data beyond day 14 pending
KYMERA R&D DAY - December 16th, 2021
7
14
Day
17
21
Placebo
25 mg QD
50 mg QD
100 mg QD
200 mg QD*
28
PAGE 34View entire presentation